What is DREAMM-7?
A landmark Phase 3 trial showing Belantamab Mafodotin (Blenrep) + Bortezomib + Dexamethasone nearly triples progression-free survival vs. Daratumumab + Bortezomib + Dexamethasone in relapsed/refractory multiple myeloma.
Multiple Myeloma Foundation
Multiple Myeloma (MM) is a clonal plasma cell malignancy. The CRAB criteria remain the definitive clinical guidelines for identifying symptomatic disease requiring systemic therapy.
Calcium
Hypercalcemia from bone lysis.
Renal
Insufficiency from M-protein burden.
Anemia
Low Hgb due to marrow crowding.
Bone
Lytic lesions and skeletal fractures.
Essential Diagnostic Workup
| Category | Test Name | What it Looks For |
|---|---|---|
| Blood Work | SPEP / SIFE | Identifies the "M-protein" (monoclonal spike). |
| sFLC Assay | Measures kappa and lambda free light chains. | |
| CMP & CBC | Checks for Hypercalcemia (C), Renal failure (R), and Anemia (A). | |
| Urine | 24-hour UPEP | Detects Bence-Jones proteins (light chains in urine). |
| Marrow | Aspirate/Biopsy | Confirms percentage and clonality; includes FISH for genetics. |
| Imaging | WB-LDCT / MRI | Whole-Body Low-Dose CT is the modern standard for finding bone lesions (B). |
Firstline Treatment & Mechanisms
For newly diagnosed multiple myeloma patients, first-line therapy typically begins with induction regimens like VRd or Dara-VRd, which combine drugs targeting different biological pathways to rapidly reduce cancer cells. Eligible patients then undergo autologous stem cell transplant (ASCT) as consolidation therapy to deepen remission. This is followed by long-term maintenance therapy with Lenalidomide to sustain the response and delay disease progression.
For nearly a decade, VRd has been the global gold standard for induction, using a three-pronged attack to hit plasma cells from different biological angles.
V (Velcade/Bortezomib)
Proteasome inhibitor that jams the cell's "trash disposal" system, leading to toxic protein buildup and apoptosis.
R (Revlimid/Lenalidomide)
Alters bone marrow microenvironment and targets Cereblon (CRBN) protein to degrade essential transcription factors.
d (Dexamethasone)
High-dose steroid that kills myeloma cells directly and synergistically boosts the efficacy of the other drugs.
The "Quad" pathway takes the VRd backbone and adds a monoclonal antibody to put a "target" on cancer cells, recruiting the immune system.
Dara (Darzalex/Daratumumab)
Anti-CD38 monoclonal antibody that binds to myeloma cell surfaces and recruits NK cells/macrophages for immune attack.
Note:For transplant-eligible patients, Autologous Stem Cell Transplant (ASCT) remains a core component of the frontline paradigm, serving as a high-intensity consolidation phase to deepen the response following initial induction with triplets like VRd or quadruplets like Dara-VRd.
Defining RRMM
Relapsed/Refractory (RRMM) describes disease return or progression while on treatment. DREAMM-7 addresses patients reaching 1st relapse who are often refractory to frontline Lenalidomide and CD38 targeting.
RRMM Therapeutic Journey
Standard of care evolution from non-specific alkylators to high-potency targeted ADCs.
Cytotoxic Era
MP was the primary option. Median survival was limited to ~3 years.
The Triplet Shift
PIs (Bortezomib) and IMiDs transformed relapsed outcomes.
CD38 Dominance
DVd (CASTOR) and DRd (POLLUX) established the global 2nd-line standard.
BCMA Targeting Therapy
CAR-T Cells, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
BCMA Targeting Therapies
BCMA (B-cell maturation antigen) is a protein highly expressed on multiple myeloma cells, making it a prime target for novel therapies. Unlike CD38, which is lost in relapsed patients, BCMA remains consistently expressed.
Three Main Approaches
Bispecific Antibodies
Bind BCMA on cancer cells and T-cells simultaneously, redirecting immune attack.
CAR-T Cells
Engineered T-cells with BCMA-targeting receptors for potent, long-lasting responses.
Antibody-Drug Conjugates (ADCs)
Antibodies deliver cytotoxic drugs directly to BCMA-expressing cells.
⚠ Manufacturing Gap
CAR-T is the most potent BCMA therapy, but manufacturing takes 6 weeks. For patients with aggressive disease, this delay may not be feasible. Bispecifics and ADCs offer faster "speed to treatment" in these scenarios.
⚖ Toxicity Trade-off
Frail patients or those with weak heart/lungs may not tolerate Cytokine Release Syndrome (CRS) from CAR-T or Bispecifics. ADCs like Belantamab provide a safer profile, trading CRS risk for manageable eye toxicity.
Spotlight: Belantamab Mafodotin (ADC)
First-in-class Antibody-Drug Conjugate (ADC) targeting BCMA.
Targeting: Antibody binds specifically to BCMA on the cell surface.
Cytotoxicity: Internalized ADC releases mafodotin to disrupt microtubules.
Role in DREAMM-7
By targeting BCMA instead of CD38, it bypasses the immune escape seen in patients failing 1L CD38-monoclonal antibodies.
Trial Evidence Analysis
Clinical Endpoint Definitions
Progression-Free Survival
Definition: Time from starting treatment until disease progresses or patient dies.
📌 How long can we keep the cancer from getting worse?
Overall Response Rate
Definition: % of patients who achieve ≥ Partial Response (PR).
Includes:
- Partial Response (PR)
- Complete Response (CR)
📌 How many patients actually respond to the drug?
Complete Response
Definition: No detectable disease using standard clinical tests.
In multiple myeloma:
- No M-protein in blood/urine
- Normal bone marrow (no clonal plasma cells)
📌 We can't see the cancer anymore with routine testing
Minimal Residual Disease Negative
Definition: No detectable cancer cells using very sensitive testing (flow cytometry or sequencing).
Sensitivity: Detects down to 1 cancer cell in 100,000 cells (10⁻⁵).
📌 Even microscopic disease is gone
Median PFS (Months)
Response Depth (%)
Grade 3/4 Adverse Events (%)
Ocular Safety Profile
What is MECs?
Microcyst-like Epithelial Changes,tiny cyst-like inclusions in the corneal epithelium that scatter light, causing visual haziness or blur. These form due to corneal cell "micropinocytosis" (accidental sipping) of the ADC from blood.
Patient Symptoms
- Blurred Vision (most common)
- Dry Eye (grittiness sensation)
- Photophobia (light sensitivity)
- Decreased Visual Acuity (line loss on eye chart)
DREAMM-7 Outcomes
Any Grade: 60–70% of patients
Grade 3/4: 34% of patients
Resolution Rate: 98% returned to baseline
Median Time: ~22 days with dose management
Management Strategy
Fully reversible. Managed via dose delays (cycle skip) or reductions, not permanent discontinuation. Preservative-free artificial tears + ophthalmologist exams before every dose.
The Clinical Verdict
Redefining the ceiling for RRMM care via early BCMA targeting.
Regimen Scorecard
Targeted Durability
Nearly triples median PFS vs Daratumumab standard.
Response Quality
Highest MRD-negativity rate ever reported in the 2nd line triplet setting.
Community Ready
Off-the-shelf ADC brings BCMA potency to community clinics.
Looking to the Future: The DREAMM Program
While DREAMM-7 (BVd) and DREAMM-8 (BPd) are currently the "stars" of the show because they secured the recent FDA approvals for early relapse, the DREAMM clinical program is expansive. As of April 2026, the focus has shifted from proving Belantamab works in late-stage patients to moving it into frontline (newly diagnosed) care and optimizing the dosing to reduce those ocular side effects.
1. The Frontline Push (Newly Diagnosed)
These are the most anticipated active trials because they aim to replace the current "Dara-VRd" or "VRd" standards.
DREAMM-9: This is a Phase 3 trial evaluating Belantamab mafodotin in combination with VRd (Bortezomib, Lenalidomide, and Dexamethasone) for patients who are transplant-eligible. The goal is to see if adding an ADC to the standard triplet can achieve deeper MRD-negativity than the current standard.
DREAMM-10: This study focuses on transplant-ineligible newly diagnosed patients. It compares the "Belantamab-Rd" (BRd) triplet against the current "Daratumumab-Rd" (DRd) gold standard established by the MAIA trial.
2. The Optimization & Safety Trials
Since ocular toxicity is the primary barrier to Belantamab use, these trials are active and specifically designed to find a "gentler" way to give the drug.
DREAMM-14: This is a critical Phase 2 "dosing" study. It is evaluating alternative schedules—such as lower doses or longer intervals between doses—to see if we can maintain the 36-month PFS seen in DREAMM-7 while significantly lowering the 34% rate of Grade 3/4 ocular events.
DREAMM-5 (The Platform Study): This is a massive, ongoing "Master Protocol" study. It tests Belantamab in combination with several novel agents (like OX40 agonists or Gamma-secretase inhibitors) to see if these boosters can make the drug work at even lower, "eye-safe" doses.